Cargando…

Erratum to: Insulin-like growth factor 1 receptor mediated tyrosine 845 phosphorylation of epidermal growth factor receptor in the presence of monoclonal antibody cetuximab

Detalles Bibliográficos
Autores principales:	Iyer, Gopal, Price, James, Bourgeois, Shay, Armstrong, Eric, Huang, Shyhmin, Harari, Paul M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131511/ https://www.ncbi.nlm.nih.gov/pubmed/27905891 http://dx.doi.org/10.1186/s12885-016-2958-x

Ejemplares similares

Insulin growth factor 1 like receptor (IGF-1R)
por: Iyer, Gopal, et al.
Publicado: (2016)

Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors
por: Fischel, J-L, et al.
Publicado: (2005)

Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer
por: Wollina, Uwe, et al.
Publicado: (2017)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Association of the tyrosine phosphorylated epidermal growth factor receptor with a 55-kD tyrosine phosphorylated protein at the cell surface and in endosomes
Publicado: (1992)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
por: Chang, Shih-Chieh, et al.
Publicado: (2011)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
por: Braig, Friederike, et al.
Publicado: (2015)

Monoclonal Antibodies against Epidermal Growth Factor Receptor in Solid Tumors
por: Saba, Nabil F., et al.
Publicado: (2012)

Profiling Epidermal Growth Factor Receptor and Heregulin Receptor 3 Heteromerization Using Receptor Tyrosine Kinase Heteromer Investigation Technology
por: Ayoub, Mohammed Akli, et al.
Publicado: (2013)

Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2
por: Tanaka, Hidekazu, et al.
Publicado: (2014)

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
por: Park, Sojung, et al.
Publicado: (2021)

A case of epidermal growth factor receptor tyrosine kinase inhibitor effectiveness in epidermal growth factor receptor mutation-positive squamous cell carcinoma
por: Matsumura, Sosuke, et al.
Publicado: (2023)

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients
por: Scartozzi, M, et al.
Publicado: (2011)

Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor
por: Dudek, A Z, et al.
Publicado: (2009)

Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
por: Chen, Gang, et al.
Publicado: (2012)

Quality of Life in Patients With Severe Skin Reactions in Course of First-Generation Epidermal Growth Factor Receptor Inhibitors Monoclonal Antibodies (Our Experience With Cetuximab)
por: De Luca, Rossella, et al.
Publicado: (2021)

Coarse-Grained Molecular Simulation of Epidermal Growth Factor Receptor Protein Tyrosine Kinase Multi-Site Self-Phosphorylation
por: Koland, John G.
Publicado: (2014)

Correction to: Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
por: Chen, Gang, et al.
Publicado: (2020)

Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma
por: KURAI, JUN, et al.
Publicado: (2012)

Enhanced Antitumor Effects of Epidermal Growth Factor Receptor Targetable Cetuximab-Conjugated Polymeric Micelles for Photodynamic Therapy
por: Chang, Ming-Hsiang, et al.
Publicado: (2018)

Impaired degradation followed by enhanced recycling of epidermal growth factor receptor caused by hypo-phosphorylation of tyrosine 1045 in RBE cells
por: Gui, Anping, et al.
Publicado: (2012)

Recruitment of epidermal growth factor receptors into coated pits requires their activated tyrosine kinase
Publicado: (1995)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Chang, Youjin, et al.
Publicado: (2013)

Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance
por: Heydt, Carina, et al.
Publicado: (2018)

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?
por: Tabbò, Fabrizio, et al.
Publicado: (2020)

Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
por: Chikaishi, Yasuhiro, et al.
Publicado: (2020)

Targeting the epidermal growth factor receptor
por: El-Rayes, B F, et al.
Publicado: (2004)

Epidermal growth factor receptor in glioblastoma
por: Xu, Hongsheng, et al.
Publicado: (2017)

Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells
por: Napolitano, Stefania, et al.
Publicado: (2017)

Cellular Functions Regulated by Phosphorylation of EGFR on Tyr845
por: Sato, Ken-ichi
Publicado: (2013)

Estrogen Receptor β1 Expression Patterns Have Different Effects on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors’ Treatment Response in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma
por: Zhang, Lijuan, et al.
Publicado: (2021)

Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas
por: Magkou, Christina, et al.
Publicado: (2008)

Annexin I is phosphorylated in the multivesicular body during the processing of the epidermal growth factor receptor
Publicado: (1993)

The Role of Epidermal Growth Factor Receptor Family of Receptor Tyrosine Kinases in Mediating Diabetes-Induced Cardiovascular Complications
por: Shraim, Bara A., et al.
Publicado: (2021)

An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer
por: Yoshimura, Akihiro, et al.
Publicado: (2018)

Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors
por: Bouchez, Clémentine, et al.
Publicado: (2020)

Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?
por: Kim, Young Hak, et al.
Publicado: (2011)

Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors
por: Chen, Justin A., et al.
Publicado: (2020)

Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
por: Abunada, Aya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fvqrf1du5082hhh552sn69t13l